Boiron SA (0DTF.L)

EUR 27.0

(-0.37%)

Operating Expenses Summary of Boiron SA

  • Boiron SA's latest annual operating expenses in 2023 was 317.27 Million EUR , down -2.05% from previous year.
  • Boiron SA's latest quarterly operating expenses in 2024 Q2 was 162.82 Million EUR , down 0.0% from previous quarter.
  • Boiron SA reported a annual operating expenses of 323.89 Million EUR in annual operating expenses 2022, up 11.62% from previous year.
  • Boiron SA reported a annual operating expenses of 290.19 Million EUR in annual operating expenses 2021, down -11.06% from previous year.
  • Boiron SA reported a quarterly operating expenses of 162.56 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Boiron SA reported a quarterly operating expenses of 160.18 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Operating Expenses Chart of Boiron SA (2023 - 2001)

Historical Annual Operating Expenses of Boiron SA (2023 - 2001)

Year Operating Expenses Operating Expenses Growth
2023 317.27 Million EUR -2.05%
2022 323.89 Million EUR 11.62%
2021 290.19 Million EUR -11.06%
2020 326.26 Million EUR -8.79%
2019 357.7 Million EUR -2.26%
2018 365.96 Million EUR -0.07%
2017 366.22 Million EUR 1.1%
2016 362.25 Million EUR -0.95%
2015 365.72 Million EUR 4.1%
2014 351.3 Million EUR -3.02%
2013 362.23 Million EUR 1.44%
2012 357.1 Million EUR 4.67%
2011 341.16 Million EUR -0.44%
2010 342.67 Million EUR 6.94%
2009 320.44 Million EUR 3.34%
2008 310.1 Million EUR 3.56%
2007 299.44 Million EUR 2.8%
2006 291.27 Million EUR 13.28%
2005 257.13 Million EUR 30.94%
2004 196.38 Million EUR -16.44%
2003 235.02 Million EUR 5.5%
2002 222.78 Million EUR 7.16%
2001 207.89 Million EUR 0.0%

Peer Operating Expenses Comparison of Boiron SA

Name Operating Expenses Operating Expenses Difference
Laboratorios Farmaceuticos Rovi, S.A. 263.09 Million EUR -20.595%
Vetoquinol SA 217.11 Million EUR -46.131%
Valneva SE 134.92 Million EUR -135.149%
AB Science S.A. 14.01 Million EUR -2163.649%
Nanobiotix S.A. 62.98 Million EUR -403.712%
PHAXIAM Therapeutics S.A. 24.98 Million EUR -1169.803%
Vivoryon Therapeutics N.V. 24.69 Million EUR -1184.922%
BioSenic S.A. 7.58 Million EUR -4084.004%
ABIVAX Société Anonyme 127.37 Million EUR -149.084%
Formycon AG 23.73 Million EUR -1236.843%